Document Classification

Section Type: METHODS

Text: Patients 12 years (N = 210) with mild to moderate-severe persistent, reversible asthma were evenly randomised to 12 weeks of treatment (b. i. d.) with fluticasone/formoterol combination therapy (100/10 g b. i. d. or 250/10 g b. i. d.) or fluticasone plus formoterol (Flixotide Evohaler, pMDI, Flovent [HFA] ; Foradil, DPI, Foradil Aerolizer) administered concurrently (fluticasone + formoterol ; 100 g + 12 g b. i. d. or 250 g + 12 g b. i. d.) in an open-label, parallel-group, multicentre study.